Literature DB >> 23560376

Incidence and prognosis of synchronous colorectal carcinomatosis.

Diane Goéré1, Marc-Antoine Allard, Charles Honoré, Frédéric Dumont, Dominique Elias.   

Abstract

The aim of this article was to review the literature on synchronous peritoneal carcinomatosis (PC) from colorectal cancer. Synchronous PC of colorectal cancer origin is a rare disease with an incidence ranging from 4 to 7% of colorectal cancer patients and is exclusively peritoneal in half of cases. Synchronous PC is more frequently associated with primary tumors that are at an advanced stage. After macroscopically complete resection (R0/R1) of synchronous PC, without associated intraperitoneal chemotherapy, the 5-year survival rates range from 24 to 36%. Complete cytoreductive surgery plus intraperitoneal chemotherapy at the time of diagnosis is probably the best therapeutic option. If no intraperitoneal treatment can be given, no resection should be performed and an accurate description should be made. If a limited synchronous PC has been resected with the primary tumor without intraperitoneal treatment, the authors recommend a systematic second-look surgery in an experienced center.

Entities:  

Mesh:

Year:  2013        PMID: 23560376     DOI: 10.2217/fon.12.206

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

Review 1.  Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?

Authors:  Chiara Molinari; Giorgia Marisi; Alessandro Passardi; Laura Matteucci; Giulia De Maio; Paola Ulivi
Journal:  Int J Mol Sci       Date:  2018-11-23       Impact factor: 5.923

2.  Using nomograms to predict prognostic factors in young colorectal mucinous and signet-ring cell adenocarcinoma patients.

Authors:  Baochun Wang; Juntao Zeng; Yuren Liu
Journal:  Biosci Rep       Date:  2019-07-18       Impact factor: 3.840

3.  Long-term outcomes and prognostic factors of young patients with mucinous and signet-ring cell colorectal cancer.

Authors:  Rui Zhang; Jian Zhao; Jian Xu; Yuzhe Chen
Journal:  Arch Med Sci       Date:  2020-03-02       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.